Modelling approach to simulate reductions in LDL cholesterol levels after combined intake of statins and phytosterols/-stanols in humans

Lipids in Health and Disease

Jan CH van Eijkeren¹  Olaf H Klungel²  Cathy JM Rompelberg¹  Simone RBM Eussen¹ 

[1] National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands;Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, P.O. Box 80082, 3508 TB Utrecht, The Netherlands

关键词: coronary heart disease;    lipids;    LDL cholesterol;    phytostanols;    phytosterols;    statins;    model;   

Others  :  1212473
DOI  :  10.1186/1476-511X-10-187

 received in 2011-08-31, accepted in 2011-10-21,  发布年份 2011

【 摘 要 】

Background

To examine the effects on LDL cholesterol of the combined use of statins and phytosterols/-stanols, in vivo studies and clinical trials are necessary. However, for a better interpretation of the experimental data as well as to possibly predict cholesterol levels given a certain dosing regimen of statins and phytosterols/-stanols a more theoretically based approach is helpful. This study aims to construct a mathematical model to simulate reductions in low-density lipoprotein (LDL) cholesterol in persons who combine the use of statins with a high intake of phytosterols/-stanols, e.g. by the use of functional foods.

Methods and Results

The proposed model includes the cholesterol pool size in the liver and serum levels of very low-density lipoprotein (VLDL) cholesterol. Both an additional and a multiplicative effect of phytosterol/-stanol intake on LDL cholesterol reduction were predicted from the model. The additional effect relates to the decrease of dietary cholesterol uptake reduction, the multiplicative effect relates to the decrease in enterohepatic recycling efficiency, causing increased cholesterol elimination through bile. From the model, it was demonstrated that a daily intake of 2 g phytosterols/-stanols reduces LDL cholesterol level by about 8% to 9% on top of the reduction resulting from statin use. The additional decrease in LDL cholesterol caused by phytosterol/-stanol use at the recommended level of 2 g/d appeared to be similar or even greater than the decrease achieved by doubling the statin dose.

Conclusion

We proposed a simplified mathematical model to simulate the reduction in LDL cholesterol after separate and combined intake of statins and functional foods acting on intestinal (re)absorption of cholesterol or bile acids in humans. In future work, this model can be extended to include more complex (regulatory) mechanisms.

【 授权许可】

   
2011 Eussen et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994, 344(8934):1383-1389.
• [2]Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366(9493):1267-78.
• [3]Amarenco P, Labreuche J, Lavalle P, Touboul P: Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004, 35(12):2902-2909.
• [4]Plat J, Mensink RP: Plant stanol and sterol esters in the control of blood cholesterol levels: mechanism and safety aspects. Am J Cardiol 2005, 96(1A):15D-22D.
• [5]Marinangeli CP, Varady KA, Jones PJ: Plant sterols combined with exercise for the treatment of hypercholesterolemia: overview of independent and synergistic mechanisms of action. J Nutr Biochem 2006, 17(4):217-24.
• [6]Dietschy JM, Turley SD, Spady DK: Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 1993, 34(10):1637-59.
• [7]Shum YY, Huang N, Walter G, Black A, Sekerke C, Chang T, Whitfield LR: Development, validation, and interlaboratory comparison of an HMG-CoA reductase inhibition assay for quantitation of atorvastatin in plasma matrices. Ther Drug Monit 1998, 20(1):41-49.
• [8]Davis H, Altmann S: Niemann-Pick C1 Like 1 (NPC1L1) an intestinal sterol transporter. Biochim Biophys Acta 2009, 1791(7):679-683.
• [9]McNamara DJ: Effects of fat-modified diets on cholesterol and lipoprotein metabolism. Annu Rev Nutr 1987, 7:273-290.
• [10]Rajaratnam RA, Gylling H, Miettinen TA: Cholesterol absorption, synthesis, and fecal output in postmenopausal women with and without coronary artery disease. Arterioscler Thromb Vasc Biol 2001, 21(10):1650-1655.
• [11]Insel P, Ross D, McMahon K, Bernstein M, (eds): Nutrition. Jones and Bartlett Publishers, Sudbury, MA; 2011.
• [12]Stipanuk MH, (ed): Biochemical and physiological aspects of human nutrition. Lipid metabolism-Synthesis and oxidation. W.B. Saunders Co., Philadelphia, USA; 2000.
• [13]van der Velde A, Brufau G, Groen A: Transintestinal cholesterol efflux. Curr Opin Lipidol 2010, 21(3):167-171.
• [14]Demirezen EM, Barlas Y: A simulation model for blood cholesterol dynamics and related disorders. 2009, 2011(12 July):1-38.
• [15]Phillips GB: The lipid composition of human bile. Biochim Biophys Acta 1960, 41:361-363.
• [16]Bisschop P, Bandsma RHJ, Stellaard F, Harmsel A, Meijer A, Sauerwein H, Kuipers F, Romijn J: Low-fat, high-carbohydrate and high-fat, low-carbohydrate diets decrease primary bile acid synthesis in humans. Am J Clin Nutr 2004, 79(4):570-576.
• [17]Sahlin S, Granstrm L, Gustafsson U, Sthlberg D, Backman L, Einarsson K: Hepatic esterification rate of cholesterol and biliary lipids in human obesity. J Lipid Res 1994, 35(3):484-490.
• [18]Sahlin S, Sthlberg D, Einarsson K: Cholesterol metabolism in liver and gallbladder mucosa of patients with cholesterolosis. Hepatology 1995, 21(5):1269-1275.
• [19]Houston JB: Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994, 47(9):1469-1479.
• [20]Kumar PJ, Clark ML: Clinical medicine - Diabetes Mellitus and other disorders of metabolism. W.B. Saunders 2002.
• [21]Berry DA, Berry SM, McKellar J, Pearson TA: Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis. Am Heart J 2003, 145(6):1036-1045.
• [22]Demonty I, Ras RT, van der Knaap HC, Duchateau GS, Meijer L, Zock PL, Geleijnse JM, Trautwein EA: Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake. J Nutr 2009, 139(2):271-84.
• [23]Blair SN, Capuzzi DM, Gottlieb SO, Nguyen T, Morgan JM, Cater NB: Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol 2000, 86(1):46-52.
• [24]Simons LA: Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-density lipoprotein cholesterol in primary hypercholesterolemia. Am J Cardiol 2002, 90(7):737-40.
• [25]Richter WO: Treatment of severe hypercholesterolemia with a combination of beta-sitosterol and lovastatin. Curr Ther Res 1996, 57(7):497-505. 497
• [26]Castro Cabezas M, de Vries JH, Van Oostrom AJ, Iestra J, van Staveren WA: Effects of a stanol-enriched diet on plasma cholesterol and triglycerides in patients treated with statins. J Am Diet Assoc 2006, 106(10):1564-9.
• [27]Goldberg AC, E OR Jr, Bateman JH, Schimmoeller L, McPherson TB, Spilburg CA: Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs. Am J Cardiol 2006, 97(3):376-9.
• [28]De Jong A, Plat J, Bast A, Godschalk RW, Basu S, Mensink RP: Effects of plant sterol and stanol ester consumption on lipid metabolism, antioxidant status and markers of oxidative stress, endothelial function and low-grade inflammation in patients on current statin treatment. Eur J Clin Nutr 2008, 62:263-73.
• [29]Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R: Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 2003, 78(8):965-78.
• [30]August E, Parker KH, Barahona M: A dynamical model of lipoprotein metabolism. Bull Math Biol 2007, 69(4):1233-1254.
• [31]Chun PW, Espinosa AJ, Lee CW, Shireman RB, Brumbaugh EE: Low density lipoprotein receptor regulation. Kinetic models. Biophys Chem 1985, 21(3-4):185-209.
• [32]Wattis JAD, O'Malley B, Blackburn H, Pickersgill L, Panovska J, Byrne HM, Jackson KG: Mathematical model for low density lipoprotein (LDL) endocytosis by hepatocytes. Bull Math Biol 2008, 70(8):2303-2333.
• [33]Theuwissen E, Mensink RP: Water-soluble dietary fibers and cardiovascular disease. Physiol Behav 2008, 94(2):285-92.
• [34]Eussen S, Klungel O, Garssen J, Verhagen H, van Kranen H, van Loveren H, Rompelberg C: Support of drug therapy using functional foods and dietary supplements: focus on statin therapy. Br J Nutr 2010, 103(9):1260-1277.
• [35]Gylling H, Miettinen TA: Baseline intestinal absorption and synthesis of cholesterol regulate its response to hypolipidaemic treatments in coronary patients. Atherosclerosis 2002, 160(2):477-81.
• [36]Eussen S, de Jong N, Rompelberg C, Garssen J, Verschuren W, Klungel O: Dose-dependent cholesterol-lowering effects of phytosterol/phytostanol-enriched margarine in statin users and statin non-users under free-living conditions. Public Health Nutr 2011, 1-10.
• [37]de Jong N, Zuur A, Wolfs MC, Wendel-Vos GC, van Raaij JM, Schuit AJ: Exposure and effectiveness of phytosterol/-stanol-enriched margarines. Eur J Clin Nutr 2007, 61:1407-15.
• [38]Richter WO, Jacob BG, Schwandt P: Interaction between fibre and lovastatin. Lancet 1991, 338(8768):706.
• [39]Eussen SRBM, Rompelberg CJM, Andersson K, Klungel O, Hellstrand P, Oste R, van Kranen H, Garssen J: Simultaneous intake of oat bran and atorvastatin reduces their efficacy to lower lipid levels and atherosclerosis in LDLr-/- mice. Pharmacological research 2011, 64(1):36-43.